U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...
RSV vaccines were 58% effective at preventing RSV-associated hospitalizations among adults age 60 or older across two seasons. Vaccine effectiveness against all-cause cardiorespiratory ...
FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...
The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...
The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...
Food and Drug Administration officials have opened a safety review of two injectable drugs used to protect babies and ...
Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...
Merck MRK continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the prevention of certain cancers caused by human papillomavirus. Though the vaccine’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback